Shares of Soleno were halted ahead of the company announcement of FDA approval of VYKATTM XR to treat hyperphagia.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics announces FDA approval of VYKATTM XR to treat hyperphagia
- Soleno Therapeutics trading halted, news pending
- Soleno Therapeutics resumed with a Buy at Stifel
- Optimistic Buy Rating for Soleno Therapeutics Amid Anticipated FDA Approval and Strong Financial Position
- Soleno Therapeutics Reports 2024 Financial Results and Strategic Progress
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue